Eltrombopag for Peripheral Blood Stem Cell Harvest
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma
patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to
answer are:
- Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell
mobilization and harvest.
- Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration,
circulating CD34+ cells during autologous hematopoietic stem cell mobilization.
Participants will receiving additional eltrombopag during stem cell harvest procedure. The
amount of harvested stem cells will be compared with historical group to see if eltrombopag
could increase the amount of harvested stem cells.